Xiaomi Shares Jump on Europe EV Expansion Plan 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Milei Threatens Falkland Oil Firms With Sanctions 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
France Targets Shein, Temu With Fast-Fashion Fees 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Add as a preferred source on Google
CAMBRIDGE, Mass., March 05, 2018 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Cowen and Company 38th Annual Health Care Conference
Monday, March 12, 2018 at 12:00 p.m. ET in Boston, MA
Barclays Global Healthcare Conference
Wednesday, March 14, 2018 at 2:35 p.m. ET in Miami, FL
A webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]
